1. Home
  2. CMPX

as 12-11-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of three product candidates, CTX-009, CTX-471, and CTX-8371.

Founded: 2014 Country:
United States
United States
Employees: N/A City: BOSTON
Market Cap: 206.3M IPO Year: N/A
Target Price: $7.67 AVG Volume (30 days): 510.2K
Analyst Decision: Strong Buy Number of Analysts: 3
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.35 EPS Growth: N/A
52 Week Low/High: $0.77 - $2.34 Next Earning Date: 11-12-2024
Revenue: $850,000 Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): 610.48%

CMPX Daily Stock ML Predictions

Share on Social Networks: